Tolerance test
Patients were clinically stable at the start of the study, and a tolerance test with the first dose of the study medication was performed for each patient at the outpatient ward. Patients were excluded if they failed the tolerance test. Study visits were planned every 3 months for 1 year, and a diary card was used every week to obtain information on the development of possible side effects (Figure All patients underwent this supervised test dose by using the InnoSpire Deluxe at the outpatient ward at visit 0 (the start of the study) to assess the occurrence of local intolerability. Patients continued their own maintenance inhaled medication during the tolerance test and next to the study medication.A spirometry measurement was performed 20 min before the first dose of the study medication. All patients received a short‐acting beta agonist (200 mcg salbutamol dose aerosol with aerochamber) 5 min before the study medication. Spirometry measurements were repeated 20 min after the use of the inhaled study medication (Figure 